- Home
- SON vs BBIO Comparison
SON vs BBIO Comparison
Compare SON & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SON
- BBIO
- Stock Information
- Founded
- SON 1899
- BBIO 2015
- Country
- SON United States
- BBIO United States
- Employees
- SON N/A
- BBIO N/A
- Industry
- SON Containers/Packaging
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SON Consumer Discretionary
- BBIO Health Care
- Exchange
- SON Nasdaq
- BBIO Nasdaq
- Market Cap
- SON 5.1B
- BBIO 5.6B
- IPO Year
- SON N/A
- BBIO 2019
- Fundamental
- Price
- SON $49.24
- BBIO $36.08
- Analyst Decision
- SON Buy
- BBIO Strong Buy
- Analyst Count
- SON 6
- BBIO 13
- Target Price
- SON $60.17
- BBIO $48.33
- AVG Volume (30 Days)
- SON 759.9K
- BBIO 2.5M
- Earning Date
- SON 02-12-2025
- BBIO 02-20-2025
- Dividend Yield
- SON 4.25%
- BBIO N/A
- EPS Growth
- SON N/A
- BBIO N/A
- EPS
- SON 2.91
- BBIO N/A
- Revenue
- SON $6,572,688,000.00
- BBIO $217,765,000.00
- Revenue This Year
- SON N/A
- BBIO $2,309.33
- Revenue Next Year
- SON $16.95
- BBIO N/A
- P/E Ratio
- SON $16.79
- BBIO N/A
- Revenue Growth
- SON N/A
- BBIO 2209.77
- 52 Week Low
- SON $45.93
- BBIO $21.62
- 52 Week High
- SON $61.73
- BBIO $41.04
- Technical
- Relative Strength Index (RSI)
- SON 54.09
- BBIO 73.73
- Support Level
- SON $46.89
- BBIO $33.73
- Resistance Level
- SON $47.95
- BBIO $36.24
- Average True Range (ATR)
- SON 0.94
- BBIO 1.63
- MACD
- SON 0.20
- BBIO 0.65
- Stochastic Oscillator
- SON 97.78
- BBIO 97.63
About SON Sonoco Products Company
Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.